Please select the eligibility criteria that correspond to the clinical trial below.
Title: Phase 2 Study Of The Effects Of Open-Label CP-690,550 And Double-Blind Atorvastatin On Lipids In Patients With Active Rheumatoid Arthritis
Brief Summary: All patients will be in instructed to eat a therapeutic lifestyle diet and will receive CP-690,550 throughout the 12 weeks of this study. After 6 weeks, half will receive the cholesterol lowering agent, atorvastatin, and half a matching placebo. This study will first measure the effects of CP-690,550 on cholesterol levels and then the effects of adding atorvastatin on those levels.


Options:
A: Inclusion Criteria:

* Discontinuation of all cholesterol lowing drugs, including dietary supplements.
* Documented history of, or high risk of coronary heart disease or other established atherosclerotic disease.

Exclusion Criteria:

* The use of lipid lowering drugs or dietary supplements after Visit 1.
* Active arterial disease eg Unstable angina, or recent arterial surgery
* Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse.
* Abnormal laboratory parameters as defined in the protocol.
B: Inclusion Criteria:

* Men and women, ages 18-79 years, inclusive
* Fasting, untreated non-high-density lipoprotein cholesterol (non-HDL-C) level above NCEP ATPIII goals
* Fasting, untreated triglyceride (TG) level in the high to very high range
* Provide written informed consent and authorization for protected health information disclosure

Exclusion Criteria:

* Pregnancy
* Use of lipid-altering drugs which cannot be stopped
* History of certain cardiovascular conditions or cardiac surgery within prior 6 months
* Body mass index above 40 kg per square meter
* Allergy or sensitivity to omega-3 fatty acids or to statin drugs
* Poorly-controlled conditions including diabetes, hypertension, or thyroid disease
* Certain muscle, liver, kidney, lung, or gastrointestinal conditions
* Certain medications
* Active cancers treated within prior 2 years (except non-melanoma skin cancer)
C: Inclusion Criteria:

* Age: 18-75 years
* Female patients must not be pregnant or breast-feeding
* Patients must be moderately overweight
* All patients must have abnormal cholesterol levels or a history of abnormal cholesterol levels as defined by the protocol.
* Patients taking medication to lower their cholesterol must be willing, in some cases, to discontinue their medications during the study Stable weight (a history of increasing or decreasing no more than 6.6 lbs \[3 kg\]) for at least 2 months prior to the study;

Exclusion Criteria

* Cancer or a history of a cancer within 5 years before screening, other than some skin cancers
* Patients planning elective surgery during the study
* Patients with a history of diabetes mellitus at study onset
* History of intolerance to, or adverse effect from atorvastatin
* History of weight loss due to stomach bypass or eating disorder
* All patients may not have had a stroke, TIA, an acute myocardial infarction, angina pectoris, coronary intervention procedure (including but not limited to angioplasty, stent placement, coronary revascularization) lower extremity bypass procedure, systemic or intracoronary fibrinolytic therapy) within 5 months of screening
D: Inclusion Criteria:

* must be diagnosed as having active rheumatoid arthritis
* agree to participate in the study and sign and informed consent document

Exclusion Criteria:

* History of serious infection within the past 6 months
* test positive for TB
* have any uncontrolled clinically significant disease or laboratory tests
* require administration of prohibited medications during the study

Answer: D